Cost-Effectiveness of Iruplinalkib versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer Patients in China
Clicks: 6
ID: 283861
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
1.5
/100
6 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #296 of 309 articles by views in Frontiers in pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 309 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background The recently completed INSPIRE trial demonstrated that iruplinalkib improved progression-free survival and intracranial antitumor activity compared with crizotinib in patients with anaplastic lymphoma kinase (ALK) -positive non-small-cell lung cancer (NSCLC). The objective of this study was to determine the potential cost-effectiveness of iruplinalkib vs. crizotinib in the Chinese healthcare setting. Methods A cost-effectiveness model was developed using the partition survival method, with three health states: progression-free survival, progressive disease, and death. Data from the INSPIRE trial were used to estimate progression-free and overall survival. Costs included drug treatment, disease management, and adverse events management. Drug costs and utilities were the main drivers of the model in the deterministic sensitivity analysis. Results Treatment with iruplinalkib versus crizotinib resulted in a gain of 0.55 life-years, 2.11 quality-adjusted life-years (QALYs), and an incremental cost of $4,325.55, resulting in an incremental cost-effectiveness ratio of $2,048.03/QALY. Drug costs and utilities were the main drivers of the model in the deterministic sensitivity analysis. From the probabilistic sensitivity analysis (PSA), iruplinalkib had a 100% probability of being cost-effective at a willingness-to-pay threshold of $13,447.89/QALY. Conclusions Compared to crizotinib, iruplinalkib is a cost-effective therapy for treatment-naïve patients with ALK-positive NSCLC.
| Reference Key |
imported_1760285539_68ebd36389c93
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Chang, Feng |
| Journal | Frontiers in pharmacology |
| Year | Year not found |
| DOI |
10.3389/fphar.2025.1651463
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.